Narrative review suggests suprachoroidal injections may improve vision and reduce edema in diabetic macular edema

This narrative review evaluates the potential role of suprachoroidal space injections as an alternative to conventional intravitreal injections for patients with diabetic macular edema. The scope includes comparing these approaches against standard therapies involving anti-vascular endothelial growth factor agents and corticosteroids.

The authors highlight several potential advantages associated with the suprachoroidal approach. These include improvements in vision, reductions in macular edema, decreased treatment frequency, and lower risks of cataract formation and elevated intraocular pressure. The review notes that these outcomes were observed in the context of the available literature.

Specific numerical data, such as absolute numbers, p-values, or confidence intervals, were not reported in the source material. Similarly, details regarding adverse events, serious adverse events, discontinuations, and overall tolerability were not reported. The review does not provide a specific sample size or follow-up duration. Consequently, the practice relevance focuses on optimizing diabetic macular edema management strategies while acknowledging the current lack of quantitative certainty.